Merkel Cell Carcinoma

Oncology
12
Pipeline Programs
8
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
6
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 9 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
3 programs
1
2
Lenvatinib Oral ProductPhase 21 trial
domatinostat in combination with avelumabPhase 2Monoclonal Antibody1 trial
GLA-SEPhase 11 trial
Active Trials
NCT02035657CompletedEst. Mar 2018
NCT04869137Active Not Recruiting26Est. Sep 2026
NCT04874831Withdrawn0Est. Sep 2025
Regeneron
RegeneronTARRYTOWN, NY
2 programs
1
1
vidutolimodPhase 22 trials
Cemiplimab-RwlcPhase 1
Active Trials
NCT06063746No Longer Available
NCT04916002Terminated77Est. Oct 2024
ImmunityBio
ImmunityBioSAN DIEGO, CA
2 programs
1
1
AvelumabPhase 2Monoclonal Antibody1 trial
AvelumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT03167164Withdrawn0Est. Dec 2021
NCT03853317Terminated9Est. Sep 2022
IB
Immatics BiotechnologiesGermany - Munich
1 program
1
Arm A: F16IL2 in combination with paclitaxelPhase 21 trial
Active Trials
NCT02054884Terminated13Est. Dec 2017
Philogen
PhilogenItaly - Monteriggioni
1 program
1
Arm A: F16IL2 in combination with paclitaxelPhase 2
Xencor
XencorPASADENA, CA
1 program
1
XmAb18087Phase 1/21 trial
Active Trials
NCT04590781TerminatedEst. Mar 2022
Sanofi
SanofiPARIS, France
1 program
1
Cemiplimab-RwlcPhase 11 trial
Active Trials
NCT04975152Active Not Recruiting36Est. Mar 2028
Design Therapeutics
1 program
1
GLA-SEPhase 1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Regeneronvidutolimod
Merck & Co.domatinostat in combination with avelumab
Merck & Co.Lenvatinib Oral Product
ImmunityBioAvelumab
Immatics BiotechnologiesArm A: F16IL2 in combination with paclitaxel
XencorXmAb18087
ImmunityBioAvelumab
SanofiCemiplimab-Rwlc
Merck & Co.GLA-SE

Clinical Trials (10)

Total enrollment: 161 patients across 10 trials

NCT04916002Regeneronvidutolimod

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Start: Nov 2021Est. completion: Oct 202477 patients
Phase 2Terminated
NCT04874831Merck & Co.domatinostat in combination with avelumab

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

Start: Nov 2021Est. completion: Sep 20250
Phase 2Withdrawn
NCT04869137Merck & Co.Lenvatinib Oral Product

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Start: May 2021Est. completion: Sep 202626 patients
Phase 2Active Not Recruiting
NCT03853317ImmunityBioAvelumab

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

Start: Feb 2020Est. completion: Sep 20229 patients
Phase 2Terminated
NCT02054884Immatics BiotechnologiesArm A: F16IL2 in combination with paclitaxel

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma

Start: Oct 2013Est. completion: Dec 201713 patients
Phase 2Terminated
NCT04590781XencorXmAb18087

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

Start: May 2021Est. completion: Mar 2022
Phase 1/2Terminated
NCT03167164ImmunityBioAvelumab

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Start: Dec 2017Est. completion: Dec 20210
Phase 1/2Withdrawn
NCT04975152SanofiCemiplimab-Rwlc

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Start: Oct 2021Est. completion: Mar 202836 patients
Phase 1Active Not Recruiting
NCT02035657Merck & Co.GLA-SE

A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

Start: Jan 2014Est. completion: Mar 2018
Phase 1Completed
NCT06063746Regeneronvidutolimod

Compassionate Use of Vidutolimod

N/ANo Longer Available

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)